Pharmacoepidemiological analysis of antifungal therapy in pregnant patients

Abstract

The ongoing antifungal therapy for pregnant patients is one of the poorly studied sections of pharmacotherapy, and in particular, clinical pharmacology. As it is known, large clinical studies are not conducted in pregnant women for ethical reasons. In addition, when prescribing antifungal drugs to pregnant women, doctors often forget that the physiological changes that occur in a woman's body can lead to changes in the pharmacokinetics of these drugs and, consequently, to a change in their effectiveness and safety, which is fraught with consequences not only for the fetus, but also for mother. The purpose of the studies is to evaluate the frequency and quality of using antifungal agents during pregnancy.